SoftBank-backed medical research technology provider 10x Genomics, valued at nearly $1.3bn as of this year, has filed to go public.

Anti-cancer antibody developer IGM has filed to raise up to $100m, weeks after securing $102m in a Haldor Topsøe-backed series C round.

Osage University Partners-backed Satsuma has filed for an $86.3m initial public offering that will fund phase 3 trials of its migraine candidate.

GlaxoSmithKline and Pfizer are in line for exits after oncology drug developer SpringWorks filed to float on the Nasdaq Global Market.

Shin Nippon spinoff Satsuma has filed for an $86.3m initial public offering that will fund phase 3 trials of its migraine candidate.

The digital gifting platform, which counts KDDI as its largest investor, expects to raise approximately $51.7m when it floats in Tokyo.

Naspers is exploring a $100m secondary investment in the fantasy sports platform, though corporate backer Tencent does not appear to be among the likely sellers.

Woodford Investment Management has reportedly reaped $24.1m on its 20% stake in University of Bristol's Ultrahaptics.

The Alphabet, Baidu, Microsoft and Qualcomm-backed hosting services provider has filed to raise $100m in its IPO, five months after raising money at a reported $3.2bn valuation.